Contrast-enhanced ultrasound shows 0.95 accuracy in distinguishing malignant from benign renal massesUltrasound imaging helps doctors tell kidney cancer from benign masses

Medical ultrasonography Published September 25, 2026 Study authors: Xu Renfan, He Yunqi, Xie Xianghuan, Chen Guangzhi PubMed ↗ DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that CEUS provides high diagnostic accuracy (0.95) for distinguishing malignant from benign renal masses.

This meta-analysis evaluated the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) in distinguishing malignant renal masses from benign ones. The analysis included 4,530 renal masses, consisting of 3,221 malignant and 1,309 benign cases. The primary finding was a diagnostic accuracy of 0.95 (95% CI, 0.93-0.97).

Secondary outcomes included a sensitivity of 0.94 (95% CI, 0.91-0.96) and a specificity of 0.85 (95% CI, 0.79-0.89). The positive likelihood ratio was 6.24 (4.54-8.56) and the negative likelihood ratio was 0.07 (0.04-0.11). The diagnostic odds ratio was 89.46 (51.66-154.94). For cystic renal masses, sensitivity was 0.99, which was higher than the 0.88 reported for solid renal masses, while specificity was 0.80, which was lower than the 0.87 reported for solid renal masses.

The authors noted significant limitations, specifically high heterogeneity for sensitivity (I2=95.91%) and specificity (I2=80.43%). Despite these limitations, the data suggest CEUS may be a useful tool for differentiating malignant from benign renal masses, particularly in cystic lesions. Clinical application should consider these heterogeneity factors when interpreting results.

When a patient is found to have a mass on their kidney, the biggest question is often whether that growth is cancerous or harmless. Getting this answer quickly and accurately is vital for deciding the next steps in treatment. Doctors are looking for reliable ways to tell the difference early on.

A large review of 4,530 renal masses found that contrast-enhanced ultrasound (CEUS) is a highly accurate tool for this task. The study showed that CEUS had a 95% accuracy rate in identifying cancer. It was particularly effective at identifying cystic masses, which are fluid-filled growths, with a 99% sensitivity rate.

While the results are promising, the data shows some variation in how well the test identifies specific types of masses. Because of this variation, doctors should still weigh these results alongside other clinical factors. This imaging technique offers a strong way to help clarify what a kidney mass might be.

What this means for you:

Contrast-enhanced ultrasound is a highly accurate way to tell if a kidney mass is cancerous or benign.

Common questions

How accurate is this ultrasound method for finding kidney cancer?

The study found that contrast-enhanced ultrasound (CEUS) has a 95% accuracy rate in distinguishing between malignant and benign renal masses. It also showed a high sensitivity of 0.94, which means it is very effective at identifying the presence of cancer when it is there.

Is this test better for certain types of kidney masses?

The results showed that CEUS is particularly effective for cystic renal masses, which are fluid-filled. For these specific masses, the sensitivity was 0.99, which is higher than the 0.88 sensitivity found for solid renal masses.

What are the limitations of using this ultrasound technique?

While the accuracy is high, the study noted significant variation in the data for both sensitivity and specificity. This means that while it is a strong tool, the results can vary depending on the specific case and the type of mass being examined.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

PMID42227142

View Original Abstract ↓

AIM: This systematic review and meta-analysis was designed to evaluate the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) in distinguishing renal cancers from benign renal masses. MATERIAL AND METHODS: Meta-regression evaluated the sources of heterogeneity across studies and subgroup analyses for individual clinical classifications were conducted. Subgroup diagnostic performance for solid vs. cystic masses was also performed. The methodological quality evaluation was performed using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2). Publication bias was assessed using the Begg funnel plot and Egger's test. RESULTS: Thirty-six articles involving 4,530 renal masses (3,221 malignant, 1,309 benign) were included in the analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.94 (0.91-0.96), 0.85 (0.79-0.89), 6.24 (4.54-8.56), 0.07 (0.04-0.11), and 89.46 (51.66-154.94), respectively. The accuracy was 0.95 (0.93-0.97). I2 values of sensitivity (I2=95.91%) and specificity (I2=80.43%) were both >50%. Subgroup analyses demonstrated that CEUS had higher sensitivity for cystic renal masses than solid renal masses (0.99 vs. 0.88), but lower specificity (0.80 vs. 0.87). No publication bias was found (p=0.123). CONCLUSION: This meta-analysis demonstrated that CEUS could be an excellent tool for differentiating between malignant and benign renal masses, particularly for cystic renal masses.

Contrast-enhanced ultrasound shows 0.95 accuracy in distinguishing malignant from benign renal massesUltrasound imaging helps doctors tell kidney cancer from benign masses

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Contrast-enhanced ultrasound shows 0.95 accuracy in distinguishing malignant from benign renal massesUltrasound imaging helps doctors tell kidney cancer from benign masses

Common questions

More on Kidney Cancer

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties